GRCE Stock Summary and Trading Ideas (Grace Therapeutics | NASDAQ:GRCE)

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Grace Therapeutics trades on the NASDAQ stock market under the symbol GRCE.

As of January 16, 2026, GRCE stock price climbed to $3.65 with 37,994 million shares trading.

GRCE has a beta of 1.61, meaning it tends to be more sensitive to market movements. GRCE has a correlation of 0.23 to the broad based SPY ETF.

GRCE has a market cap of $56.48 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that GRCE belongs to (by Net Assets): VTI.

GRCE has underperformed the market in the last year with a price return of +8.6% while the SPY ETF gained +18.1%. However, in the short term, GRCE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.7% vs +5.0% return in SPY. But in the last 2 weeks, GRCE shares have been beat by the market, returning -0.3% compared to an SPY return of +1.2%.

GRCE support price is $3.50 and resistance is $3.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRCE shares will trade within this expected range on the day.